ANI Pharmaceuticals, Inc. (“ANI”) launches Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg. The current annual U.S. market for this product is approximately $342 million, according to IQVIA.     “This is our first generic product launch for 2020 and comes from the portfolio of commercial and pipeline drugs that we recently acquired.  The product was developed by Inventia Healthcare Limited as part of a two-drug development, manufacturing and commercializati...